Redefining Targeted Cancer Delivery
By harnessing the natural biological advantages of pentameric IgM antibodies, we aim to enhance tumor selectivity, reduce off-target exposure, and improve therapeutic outcomes for patients with cancer.
Mechanism of action
Delivering Therapies Where They Matter Most
Our antibody delivers cancer drugs directly to tumors, increasing drug accumulation where it matters most while reducing exposure to healthy tissues. As a combination approach, it is designed to improve the efficacy and safety of existing oncology therapies.
